7Th European Conference on Schizophrenia Research: Time For
Total Page:16
File Type:pdf, Size:1020Kb
SUPPLEMENT 1 TO VOLUME 269 Á 2019 7thEuropeanConferenceon Schizophrenia Research – Schizophrenia and other psychotic disorders: Time for precision medicine? 26–28 September 2019, Berlin, Germany Guest Editors Wolfgang Gaebel • Wolfgang Wo¨lwer • Viktoria Toeller (Du¨sseldorf, Germany) European Scientific Association on Schizophrenia and other Psychoses (ESAS) Head Office c/o Department of Psychiatry and Psychotherapy Heinrich-Heine-University Du¨sseldorf LVR Klinikum Du¨sseldorf Bergische Landstrasse 2 40629 Du¨sseldorf, Germany E-Mail: [email protected] www.esasnet.eu 123 ORGANISATION/COMMITTEES Organisation European Scientific Association on Advisory Programme Committee Schizophrenia and other Psychoses (ESAS) President: W. Gaebel, Du¨sseldorf, Germany George Awad, Canada Dinesh Bhugra, UK In cooperation with: Gerd Buchkremer, Germany George Christodoulou, Greece World Psychiatric Association (WPA) and its Peter Falkai, Germany Section on Schizophrenia Wagner F. Gattaz, Brazil European Psychiatric Association (EPA) and its Birte Glenthjo, Denmark Section on Schizophrenia Philippe Gorwood, France German Association for Psychiatry, Psycho- Heinz Ha¨fner, Germany therapy, and Psychosomatics (DGPPN) Cyril Ho¨schl, Czech Republic Asian College of Schizophrenia Research (ACSR) Valery Krasnov, Russia Competence Network on Schizophrenia (CNS) Shoˆn Lewis, UK Jan Libiger, Czech Republic Wolfgang Maier, Germany Scientific Secretariat Mario Maj, Italy Stephen Marder, USA Wolfgang Gaebel, Du¨sseldorf, Germany Patrick McGorry, Australia Wolfgang Wo¨lwer, Du¨sseldorf, Germany Andreas Meyer-Lindenberg, Germany Viktoria Toeller, Du¨sseldorf, Germany Hans-Ju¨rgen Mo¨ller, Germany Merete Nordentoft, Denmark Sir Michael Owen, UK Scientific Programme Committee Victor Peralta, Spain Norman Sartorius, Switzerland Wolfgang Gaebel, Germany Frank Schneider, Germany Silvana Galderisi, Italy Masatoshi Takeda, Japan Oliver Howes, UK, Pichet Udomratn, Thailand Joachim Klosterko¨tter, Germany Eva-Meisenzahl-Lechner, Germany Wulf Ro¨ssler, Switzerland Congress President Bernard Sabbe, Belgium Werner Strik, Switzerland Wolfgang Gaebel, Du¨sseldorf, Germany Wolfgang Wo¨lwer, Germany The supplement was not sponsored by third parties with commercial interests. The costs for publication were fully covered by delegates’ payments of registration fees. 123 CONTENTS Plenary Lectures PL-01 Transdiagnostic genomics for precision medicine in psychiatry PL-02 Inflammation in psychotic disorders: triggers and targets PL-03 Classifying psychotic disorders: a critical appraisal of the RDoC-approach Discussion D-01 ‘Precision’ or ‘personalized’ psychiatry: different terms—same content? State-of-the-Art Lectures SA-01 Systems neuroscience of psychosis—Mapping schizophrenia onto the brain SA-02 Pharmacological treatment strategies in case of non-response SA-03 Emerging precision in targets and dosages of psychotherapies for prevention and therapy of psychosis SA-04 Physical therapy in schizophrenia SA-05 Identifying and diagnosing individuals at risk of psychosis SA-06 Is early recognition in affective disorders possible? Symposia S-01 Innovations in the assessment of negative symptoms: the ways forward S-02 Schizotypy and clinical high risk for psychosis—states, traits and their interplay S-03 Accelerated aging in schizophrenia and major psychoses: using novel imaging markers for precision psychiatry S-04 Copying with uncertainty: functional approaches to decipher the underlying mechanisms of aberrant decision-making in schizophrenia S-05 Clinical high risk for psychosis in children and adolescents: findings of the Bi-national Evaluation of At- Risk Symptoms in children and adolescents (BEARS-Kid) study S-06 Pathophysiology and treatment of cognitive dysfunction in schizophrenia—new perspectives? S-07 Secondary vs primary negative symptoms: implications for precision medicine S-08 Moving from research to routine mental healthcare: the implementation of lifestyle interventions in people with severe mental illness S-09 Exploring the links between the immune system, dopamine and the environment translational implications for schizophrenia research S-10 Pathobiology, measurement and treatment of motor signs in psychosis S-11 Schizophrenia and cancer. The role of microRNAs S-12 5 years of PRONIA: what have we learned? S-13 Dopaminergic dysfunction and its functional implications S-14 Visual perceptual dysfunction in schizophrenia: psychophysical, neurobiological and computational perspectives S-15 Update on the newly published S3 guideline of schizophrenia S-16 Basic symptoms in research and clinic: past, presence and future S-17 The impact of social adversity on psychosis-like experiences along the normal to clinical continuum—a biological and behavioural analysis of social reactivity 123 S-18 The aberrant Salience-hypothesis and the clinical high-risk state of schizophrenia S-19 Targeting patients’ specific brain networks for psychotic symptoms: moving towards precision and personalized rTMS S-20 Novel approaches and methods to schizophrenia spectrum neurobiology: translation and precision psychiatry S-21 Status and perspectives on early detection and intervention in at risk mental state and first episode psychosis S-22 Paradigm and model contests in psychosis research: categories, dimensions or constructs S-23 Computational models of aberrant belief formation in psychosis S-24 The frontline of research on negative symptoms S-25 Neuroinflammation in severe mental disorders—from diagnosis to therapy S-26 Translational electrophysiology in schizophrenia: predictors and models can lead to subject-specific mechanisms S-27 Early detection and intervention of psychosis in Germany: different perspectives in clinical and research areas S-28 Moving beyond the orthodoxy: periodic catatonia as a valid phenotype S-29 Paranoia: cognitive and emotional processes in focus Educational Courses C-01 Artificial intelligence / Machine learning in psychiatry C-02 How to understand and use the new ICD-11—psychotic disorders Oral Presentations O-01 Genetics and neurobiology O-02 Epidemiology and psychopathology O-03 Neuroimaging O-04 Neuropsychology O-05 Treatment and mental health care O-06 Early recognition and prediction O-07 Outcome Poster Sessions P-01 Psychopathology P-02 Outcome and stigma I P-03 Neuroimaging and psychophysiology I P-04 Neuropsychology I P-05 Psychosocial treatment P-06 Neuroimaging and psychophysiology II P-07 Neuropsychology II P-08 Neurobiology and genetics P-09 Early recognition and prediction P-10 Diagnosis and comorbidity P-11 Drug and alternative treatment P-12 Outcome and stigma II Author Index 123 Eur Arch Psychiatry Clin Neurosci (2019) 269 (Suppl 1):S1–S101 DOI 10.1007/s00406-019-01045-6 EDITORIAL As congress president and on behalf of the Scientific diagnostic issues including new approaches like biomark- Committee and the organisers, I cordially welcome you to ers and respective methododologies, as well as phenotypic the 7th European Conference on Schizophrenia Research, or psychosocial characteristics and resulting therapeutic which this time is guided by the motto ‘‘Schizophrenia strategies. and other psychotic disorders: time for precision The ECSR is being established as an ideal platform to medicine?’’ present new data and findings of schizophrenia research. In recent years, psychiatric research mainly focuses on Accordingly, the ECSR 2019 is supposed to be the perfect approaches apt to target therapies to the individual and to forum for scientific exchange on all facets of our motto predict the course of illness from an early stage on. including remaining challenges and unsolved questions. Respective concepts have been labelled as personalised or Thus, plenary lectures, state-of-the-art lectures, and the individualised. Nowadays, driven by new diagnostics and debate on ‘‘Precision or personalized psychiatry: different therapeutics, the more comprehensive term of precision terms—same content?’’ are devoted to present potentials medicine came out on top. It takes into account individual and limitations of the paradigm of precision medicine in variation in genetic and neurobiological make-up, envi- psychiatry and especially in psychoses. The critical ronmental particularities, and lifestyle issues for each appraisal of current evidence of precision medicine in person in order to be able to predict more accurately which psychoses provided also in a variety of symposia will lead treatment and prevention strategies for a specific disorder to discuss a respective research agenda. The opportunity to will work in which groups of people with similar clinical meet with international experts might even result in the presentations. Since psychoses in general and schizophre- initiation of consortia to cooperate on relevant topics fur- nia in particular present as quite heterogeneous disorders a ther promoting precision medicine in schizophrenia common ‘‘one-fits-all’’ approach obviously is not able to diagnostics, therapies and care, finally translating new meet individual needs. knowledge into better outcomes. By deciding on a respective motto for the upcoming I cordially invite you to join us and participate in this ECSR questioning whether time for precision medicine has exciting event. already come with regard to schizophrenia and other psy- Sincerely yours, choses, we aim to evaluate current evidence emerging from technological advances and various disciplines like (phar- Wolfgang Gaebel maco)genetics, imaging, drug treatment, specific Congress President and psychotherapies, etc.